MLN8237, a specific inhibitor of Aurora-A kinase, is proved to be a potential treatment strategy for hepatocellular carcinoma (HCC). Nanogels improve the efficacy of doxorubicin. Therefore, this study aims to investigate the increase in the effect of nanogels on MLN8237 in inhibiting HCC. Doxorubicin or MLN8237 was used as an anti-tumor drug models which were packaged by organic solvent volatilization method to obtain the doxorubicin-loaded nanogel and the MLN8237-loaded nanogel. Subsequently, CCK8 assay, cell cycle assay, apoptosis assay, real-time PCR, western blotting assay and animal experiments were used to detect the effects of MLN8237 nanogel on the proliferation, cell cycle, apoptosis, tumor growth, mRNA and protein levels of aurora-A and PUMA, and AKT phosphorylation levels in HCC cell lines. The results show that the nanogels can realize pH-regulated hydrophobicity reversal, have certain stability, and can realize lysosomal escape. Moreover, the MLN8237-loaded nanogel has a stronger ability to inhibit HCC cell proliferation, block cell cycle, promote apoptosis and inhibit tumor growth than free MLN8237 by suppressing aurora-A and AKT phosphorylation. In short, nanogel can enhance the efficacy of MLN8237.
YangHWangQHuangS, et al.Smart pH/redox dual-responsive nanogels for on-demand intracellular anticancer drug release. ACS Appl Mater Interfaces2016; 8(12): 7729–7738.
4.
ZhangKWangTZhouH, et al.A novel Aurora-A inhibitor (MLN8237) synergistically enhances the antitumor activity of sorafenib in hepatocellular carcinoma. Mol Ther Nucleic Acids2018; 13: 176–188.
5.
MaluccioMCoveyA. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin2012; 62(6): 394–399.
6.
ManfrediMGEcsedyJAChakravartyA, et al.Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res2011; 17(24): 7614–7624.
7.
NairJSSchwartzGK. MLN-8237: a dual inhibitor of aurora A and B in soft tissue sarcomas. Oncotarget2016; 7(11): 12893–12903.
8.
PalaniSPatelMHuckJ, et al.Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol2013; 72(6): 1255–1264.
9.
CarmenaMEarnshawWC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol2003; 4(11): 842–854.
10.
MarumotoTHondaSHaraT, et al.Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem2003; 278(51): 51786–51795.
11.
MarumotoTZhangDSayaH. Aurora-A - a guardian of poles. Nat Rev Cancer2005; 5(1): 42–50.
12.
DeesECCohenRBvon MehrenM, et al.Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res2012; 18(17): 4775–4784.
13.
SellsTBChauREcsedyJA, et al.MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora a inhibitors. ACS Med Chem Lett2015; 6(6): 630–634.
14.
BertrandNWuJXuX, et al.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev2014; 66: 2–25.
15.
JiTZhaoYDingY, et al.Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv Mater2013; 25(26): 3508–3525.
16.
PeerDKarpJMHongS, et al.Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol2007; 2(12): 751–760.
17.
TorchilinVP. Multifunctional nanocarriers. Adv Drug Deliv Rev2006; 58(14): 1532–1555.
18.
BochotAFattalE. Liposomes for intravitreal drug delivery: a state of the art. J Contr Release2012; 161(2): 628–634.
19.
ZhangCYYangYQHuangTX, et al.Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery. Biomaterials2012; 33(26): 6273–6283.
20.
MengFZhongZFeijenJ. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules2009; 10(2): 197–209.
21.
KabanovAVVinogradovSV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed Engl2009; 48(30): 5418–5429.
22.
YallapuMMJaggiMChauhanSC. Design and engineering of nanogels for cancer treatment. Drug Discov Today2011; 16(9-10): 457–463.
23.
OishiMNagasakiY. Stimuli-responsive smart nanogels for cancer diagnostics and therapy. Nanomedicine2010; 5(3): 451–468.
24.
GuYLeeWShenJ. Site-2 protease responds to oxidative stress and regulates oxidative injury in mammalian cells. Sci Rep2014; 4: 6268.
25.
XuXZhengS. MiR-887-3p Negatively Regulates STARD13 and Promotes Pancreatic Cancer Progression. Cancer Manag Res2020; 12: 6137–6147.
26.
PangRTseEPoonRT. Molecular pathways in hepatocellular carcinoma. Cancer Lett2006; 240(2): 157–169.
27.
MrowczynskiODPayneRABourcierAJ, et al. Targeting IL-13Rα2 for effective treatment of malignant peripheral nerve sheath tumors in mouse models. J Neurosurg. 2018; 130(2): 465–475.
28.
WangRWangJHChuXY, et al.Expression of STK15 mRNA in hepatocellular carcinoma and its prognostic significance. Clin Biochem2009; 42(7-8): 641–647.
29.
GaoPWangRShenJJ, et al.Hypoxia-inducible enhancer/alpha-fetoprotein promoter-driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. Cancer Sci2008; 99(11): 2209–2217.
30.
ZhangKChenJChenD, et al.Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget2014; 5(24): 12916–12935.
31.
YapTAYanLPatnaikA, et al.First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol2011; 29(35): 4688–4695.
32.
PandeyVBhaskaraVKBabuPP. Implications of mitogen-activated protein kinase signaling in glioma. J Neurosci Res2016; 94(2): 114–127.
33.
LeiYYWangWJMeiJH, et al.Mitogen-activated protein kinase signal transduction in solid tumors. Asian Pac J Cancer Prev APJCP2014; 15(20): 8539–8548.
34.
LaliFVHuntAETurnerSJ, et al.The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem2000; 275(10): 7395–7402.
35.
BirkenkampKUTuytLMLummenC, et al.The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol2000; 131(1): 99–107.
36.
ZhangHChenGGZhangZ, et al.Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis2012; 17(4): 325–334.
37.
ShoreSRaratyMGGhanehP, et al.Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther2003; 18(11-12): 1049–1069.
38.
LeeSMParkHChoiJW, et al.Multifunctional nanoparticles for targeted chemophotothermal treatment of cancer cells. Angew Chem Int Ed Engl2011; 50(33): 7581–7586.
39.
LiFYangHBieN, et al.Zwitterionic temperature/redox-sensitive nanogels for near-infrared light-triggered synergistic thermo-chemotherapy. ACS Appl Mater Interfaces2017; 9(28): 23564–23573.
40.
WangMThanouM. Targeting nanoparticles to cancer. Pharmacol Res2010; 62(2): 90–99.
41.
RahmanMAhmadMZKazmiI, et al.Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr Drug Discov Technol2012; 9(4): 319–329.
42.
DrbohlavovaJChomouckaJAdamV, et al.Nanocarriers for anticancer drugs--new trends in nanomedicine. Curr Drug Metabol2013; 14(5): 547–564.
43.
XiaoLXiongXSunX, et al.Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials2011; 32(22): 5148–5157.
44.
LiWShiJZhangC, et al.Co-delivery of thioredoxin 1 shRNA and doxorubicin by folate-targeted gemini surfactant-based cationic liposomes to sensitize hepatocellular carcinoma cells. J Mater Chem B2014; 2(30): 4901–4910.
45.
NukolovaNVOberoiHSCohenSM, et al.Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials2011; 32(23): 5417–5426.
46.
ChenHZhuHHuJ, et al.Highly compressed assembly of deformable nanogels into nanoscale suprastructures and their application in nanomedicine. ACS Nano2011; 5(4): 2671–2680.
47.
VendittoVJSzokaFC. Cancer nanomedicines: so many papers and so few drugs. Adv Drug Deliv Rev2013; 65(1): 80–88.
